Prevention of recurrence of
urinary tract infections by Uro-Vaxom is recommended by domestic and international guidelines; up to date, however, there is no reasonable standard regimen for the use of
drug, and long-term results of immunoprophylaxis were not evaluated. The study included 48 patients who received a first course of Uro-Vaxom 5 years ago (2007-2008), including 19 men with
chronic bacterial prostatitis/urethroprostatitis and 29 women with recurrent
cystitis. Over 5 years, 125 recurrences of urogenital
infection were observed; Uro-Vaxom along with
antibiotics or uroseptics in combination with phytopreparations was used in 88 (70.4%) cases, and in the remaining 37 (29.6%) cases monotherapy with Uro-Vaxom was used for the relief of inflammatory processes. During the follow-up period, 254 1-month courses of treatment with Uro-Vaxom were conducted; 125 (49.2%) courses were assigned for the treatment of recurrent urogenital
infection, and 129 (50.8%)--for the prevention without exacerbation of underlying disease. The main indications for use were intercurrent
infection, mainly respiratory--86 (66.7%) cases, stress--14 (10.8%); in 29 (22.5%) cases, the patients have received Uro-Vaxom focusing on their feelings without a doctor's prescription.